Drug Profile
Research programme: glutathione-independent formaldehyde dehydrogenase inhibitors - SAJE Pharma
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator SAJE Pharma
- Class Anti-inflammatories
- Mechanism of Action Glutathione-independent formaldehyde dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Unspecified
Most Recent Events
- 31 Aug 2023 Preclinical development for Inflammation and other indications is ongoing in USA (SAJE Pharma pipeline, August 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Inflammation in USA
- 28 Apr 2020 No recent reports of development identified for preclinical development in Unspecified in USA